Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 198

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Neuroblastoma

Not recruiting

Study on the Safety of Lutetium (177Lu) Oxodotreotide with Arginine and Lysine in Children with Refractory or Recurrent Neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Lysine Hydrochloride
  • Sponsor:Oncopole Claudius Regaud

Acute myeloid leukaemia

Not recruiting

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Chronic lymphocytic leukaemia

Not recruiting

Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Ospedale San Raffaele S.r.l.

Chronic lymphocytic leukaemia+1

Not recruiting

Study on Ibrutinib and Venetoclax for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.

Non-small cell lung cancer+4

Not recruiting

Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Non-small cell lung cancer+1

Not recruiting

Study of Osimertinib and Savolitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Osimertinib Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Phaeochromocytoma

Not recruiting

Study on [18F]mFBG PET-CT Imaging for Patients with Pheochromocytoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:M-(18F)-fluorobenzylguanidine
  • Sponsor:Universitair Medisch Centrum Utrecht

Triple negative breast cancer+1

Not recruiting

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Gastrointestinal stromal tumour

Not recruiting

Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine
  • Sponsor:Idrx Inc.

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Breast cancer metastatic

Not recruiting

Study of Abemaciclib and Tamoxifen in Women with Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

B-cell lymphoma+13

Not recruiting

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fadraciclib
  • Sponsor:Cyclacel Limited

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.